Drug-Induced Liver Toxicity

Overview of Mechanisms of Drug-Induced Liver Injury (DILI) and Key Challenges in DILI Research.- Detection, Elimination, Mitigation, and Prediction of Drug-Induced Liver Injury in Drug Discovery.- Drug-Induced Liver Injury (DILI) Classification and Its Application on Human DILI Risk Prediction.- Physicochemical Properties and Structural Alerts.- Quantitative Structure-Activity Relationship Models for Predicting Risk of Drug-Induced Liver Injury in Humans.- An Introduction to DILIsym® Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury.- Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities.- Use of Liver-Derived Cell Lines for the Study of Drug-Induced Liver Injury.- Evaluation of Drug-induced Liver Injuries (DILI) with Human Hepatocytes: Scientific Rationale and Experimental Approaches.- Status and Use of Induced Pluripotent Stem Cells (iPSCs) in Toxicity Testing.- Engineered Human Liver Co-Culturesfor Investigating Drug-Induced Liver Injury.- Status and Future of 3D Cell Culture in Toxicity Testing.- Reactive Metabolite Assessment in Drug Discovery and Development in Support of Safe Drug Design.- In Vitro Assessment of Mitochondrial Toxicity to Predict Drug-Induced Liver Injury.- Bile Salt Export Pump: Drug-Induced Liver Injury and Assessment Approaches.- High Content Screening for Prediction of Human Drug-Induced Liver Injury.- Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge.- Perspectives on the Regulatory and Clinical Science of Drug-Induced Liver Injury (DILI).- Regulatory Toxicological Studies: Identifying Drug-Induced Liver Injury Using Nonclinical Studies.- Hy’s Law and eDISH for Clinical Studies.- Variability in Baseline Liver Test Values in Clinical Trials: Challenges in Enhancing Drug-Induced Liver Injury Assessment in Subjects with Liver Disease.- Postmarketing Surveillance of Drug-Induced Liver Injury.- HostRisk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties.- Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI).- Immune Mechanisms in Drug-Induced Liver Injury.- Translational and Mechanistic Biomarkers of Drug-Induced Liver Injury.- Causality Assessment Methods in Drug-Induced Liver Injury.- Circulating MicroRNAs as Novel Biomarkers of Drug-Induced Liver Injury in Humans.- Systems Microscopy Approaches in Unraveling and Predicting Drug-Induced Liver Injury (DILI).- Non-Invasive Pre-Clinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury.